Patient-derived tumor organoids are generated by tumor tissue removed from patients being further grown in the laboratory, in the form of 3D structures in a gel-based growth medium. This allows the cells to develop more naturally than when grown in conventional 2D models. Compared to animal models, organoids are less complex, but more efficient in terms of time and costs. Organoids can therefore be established for several individual patients, which can hopefully lead to patient-specific treatment.

In our research group, we are now working on establishing organoid cultures generated from pseudomyxoma peritonei (PMP) patient-derived xenografts (PDX) models. The organoids are, among others, characterized by the use of fluorescent confocal microscopy and immunohistochemistry to investigate mucin production, protein expression, and to evaluate drug response.



Page visits: 142